[Level of evidence for therapeutic drug monitoring of everolimus].

Abstract : Everolimus has proven efficacy for prevention of rejection in adult de novo renal and cardiac transplant recipient in combination with ciclosporine and corticosteroids. Therapeutic drug monitoring (TDM) with target trough concentration (C0) value from 3 to 8 µg/L has been proposed. Through a systematic review of the literature, this work explored a level of recommendation for this TDM. Everolimus exhibits both wide interindividual pharmacokinetic variability and poor relationship between dose and exposure. A good relationship has been reported between C0 values and global exposure to the drug (i.e. AUC). Although C0 > 3 µg/L has been associated with a decreased incidence of rejection, the upper limit of 8 µg/L has never been formally validated. No clinical trial testing other exposure indices or comparing efficacy and/or toxicity of everolimus therapy with and without TDM has been published so far. Consequently the level of recommendation for everolimus monitoring is "recommended".
Type de document :
Article dans une revue
Thérapie, EDP Sciences, 2011, 66 (1), pp.57-61. 〈10.2515/therapie/2010025〉
Liste complète des métadonnées

Contributeur : Pierre Marquet <>
Soumis le : jeudi 9 janvier 2014 - 15:08:58
Dernière modification le : jeudi 15 février 2018 - 08:48:14

Lien texte intégral




Françoise Goirand, Bernard Royer, Anne Hulin, Franck Saint-Marcoux. [Level of evidence for therapeutic drug monitoring of everolimus].. Thérapie, EDP Sciences, 2011, 66 (1), pp.57-61. 〈10.2515/therapie/2010025〉. 〈inserm-00926387〉



Consultations de la notice